The key products and services being delivered under this federal contract IDV award are pharmaceutical drugs, specifically HETLIOZ (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. The prime contractor, Vanda Pharmaceuticals Inc., is a for-profit organization that specializes in pharmaceutical manufacturing and has established itself as a key supplier of these specialized products to the U.S. Department of Veterans Affairs (VA).
The contract, a Federal Supply Schedule (FSS) with a ceiling value of $16,131,060.00, covers drugs, pharmaceuticals, and hematology-related products, and has an ultimate completion date of August 31, 2029. Vanda Pharmaceuticals also holds two Blanket Purchase Agreements (BPAs) awarded by the VA National Acquisition Center, with ceiling values of $3,753,465.00 and $3,069,780.00, specifically for the procurement of HETLIOZ. These IDVs provide a streamlined mechanism for VA agencies to order the specialized medication, ensuring consistent availability for eligible veterans with specific sleep disorders.
Generated 2/11/25, 10:09 AM